Allurion appoints R. Jason Richey to Board as Class II director

ALLURION TECHNOLOGIES, INC.

Board size increased from 8 to 9; Richey appointed effective December 30, 2024.
Richey is an independent consultant to RTW Investments, a company stockholder.
Previously president/CEO of Cytrellis Biosystems and president of Cutera (CUTR).
Compensation consistent with Allurion's non-employee director compensation policy.
No other arrangement or material interest in transactions with the company.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

R. Jason Richey

Class II Director

ALUR · ALLURION TECHNOLOGIES, INC.

Effective: 2024-12-30
Filed: January 6, 2025, 6:59 PM ET

appointed R. Jason Richey to the Board as a Class II director

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

R. Jason Richey was appointed as Class II Director at ALLURION TECHNOLOGIES, INC..

Action: appointed
Role: Class II Director

Exact text from the filing

appointed R. Jason Richey to the Board as a Class II director

View on SEC.gov

ALLURION TECHNOLOGIES, INC. filing history →

Source: SEC EDGAR

accession 0001193125-25-002254

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.